Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330314 · ClinicalTrials.gov registry record · Phase 1
Molar Potency Study of HM12460A in Healthy Subjects
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03330314 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 38 participants.
The verdict
NCT03330314, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
Interventions
- BIOLOGICAL HM12460A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330314
The ClinicalTrials.gov registry entry for NCT03330314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HM12460A is the first listed.
NCT03330314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330314 about?
NCT03330314 is a clinical study titled "Molar Potency Study of HM12460A in Healthy Subjects". This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
What is the current status of trial NCT03330314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-10-24. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT03330314?
The interventions under investigation include: HM12460A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03330314?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.